US 10,376,603 B2
Engineered fluorinated biomaterials
Jin Kim Montclare, New York, NY (US); Joseph A. Frezzo, Brooklyn, NY (US); Cynthia Xu, Bridgewater, NJ (US); and Youssef Zaim Wadghiri, New York, NY (US)
Assigned to New York University, New York, NY (US)
Filed by New York University, New York, NY (US)
Filed on Jul. 18, 2016, as Appl. No. 15/212,599.
Claims priority of provisional application 62/193,852, filed on Jul. 17, 2015.
Prior Publication US 2017/0014351 A1, Jan. 19, 2017
Int. Cl. A61K 9/51 (2006.01); A61K 47/42 (2017.01); A61K 47/64 (2017.01); A61K 49/14 (2006.01); A61K 51/08 (2006.01); C07K 14/78 (2006.01); A61K 31/704 (2006.01)
CPC A61K 51/08 (2013.01) [A61K 9/5169 (2013.01); A61K 31/704 (2013.01); A61K 47/42 (2013.01); A61K 47/6435 (2017.08); A61K 49/14 (2013.01); C07K 14/78 (2013.01); C07K 2319/00 (2013.01)] 22 Claims
1. A protein polymer comprising from N- to C-terminus:
a coiled coil domain of cartilage oligomeric matrix protein (COMPcc) or a variant thereof selected from the group consisting of SEQ ID NOs: 3-14;
a linker sequence up to 30 amino acids, wherein the linker sequence comprises RGD and AT repeats and the RGD is directly N-terminal to the first AT repeat; and
an elastin-like peptide domain comprising the sequence [(VPGXG)2VPGXG(VPGXG)2]n (SEQ ID NO:30), wherein n can be from 2 to 24, and X is any amino acid other than proline,
wherein one or more leucine residues in the protein polymer are fluorinated.